ghk-cu tolerance downregulation desensitization long-term use effectiveness Peptide: Clinical Evidence & Injectable Protocols GHK-Cu Clinical Profile | Copper
Description
Nat Rev Drug Discovery 20:309325 Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y et al (2019) A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma
What is DSIP peptide
What this protocol cannot promise No published human trial measures GLOW outcomes
For guidance on the broader landscape of peptides used in metabolic and hormonal health, see Peptides for Insulin Resistance: GLP-1, Tesamorelin & Emerging Compounds
